Vaxira / Racotumomab https://www.ncbi.nlm.nih.gov/pubmed/25420897 https://www.ncbi.nlm.nih.gov/pubmed/25420897 https://www.frontiersin.org/articles/10.3389/fo

Vaxira / Racotumomab https://www.ncbi.nlm.nih.gov/pubmed/25420897 https://www.ncbi.nlm.nih.gov/pubmed/25420897 https://www.frontiersin.org/articles/10.3389/fonc.2012.00150/full https://www.frontiersin.org/articles/10.3389/fonc.2012.00150... This drug has completed a limited Phase II study in 2014 (71 patients), adding about 5 months of life over the control group (11 mo vs 6 mo). Then it began a large international phase III NSCLC (lung) study which apparently hasn't ended yet. It's approved for use in Cuba and Argentina, probably only for lung cancer.